, /PRNewswire/ - member of (DPG) one of the few anchor companies selected by the Government of for its Global Hypergrowth Project, is pleased to announce the expansion of its UNIK Support Program specialty pharmacy network to now include both Accredo Health Group and CVS Specialty. UNIK Support offers specialized services to benefit patients including a copay savings program, patient care liaison services, mail order pharmacy and other support services. In addition, has recently added Pheburane® to its Medicaid Preferred Drug List.
As a result, 48 State Medicaid programs now cover Pheburane®, including 12 State Medicaid programs that have included Pheburane® as a preferred covered agent for the treatment of certain UCD patients. Additionally, ~80% of commercially insured Americans have access to Pheburane® coverage, of which more than 75% is preferred coverage. Pheburane® is an innovative adjunctive therapy consisting of very small coated oral pellets (about the size of sugar crystals) for the chronic management of adult and pediatric patients with UCDs involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC) or argininosuccinate synthetase (AS).
Pheburane® is not indicated for the treatment of acute hyperammonemia. The most common side effects associated with sodium phenylbutyrate are menstrual dysfunction, decreased appetite, body odor and bad taste or taste aversion. Available in since 2013 and in since 2015, Pheburane® has a pr.
